KEEP TRADING SIMPLE - XGNBottom # 1 - Declining Volume - Exhausted Motive - Bottom #2 - Climbing Volume - Taking Advantage of corrective action.
XGN trade ideas
Exagen (bottom?)Ce
I appreciate your attention to my analysis.
I find the charts intriguing, particularly the concepts of "total destruction" and "buying in blood." Despite the short-term risks, the potential for significant gains, such as 10x, 50x, or even 100x returns in the long term, is undeniable.
Upon closer examination of the chart, it appears that shorting activities have lost momentum recently, while earnings have shown consistent growth, with approximately 92% in the green. Although attempts to initiate a short squeeze in recent months resulted in a bull trap, the current situation presents a crucial juncture that appears heavily bearish, yet potentially ripe for the taking.
Regarding the skepticism surrounding the possibility of the stock reaching $1, the remarkably low market cap suggests an underestimation of its potential. I firmly believe that this stock's trajectory is far from its conclusion; rather, it signals the dawn of a promising future.
(Exagen Inc. is a diagnostic company specializing in autoimmune diseases, notably lupus and rheumatoid arthritis.)
EXAGEN (XGN) 🌶️10$-50$ target 🎯
The recent annual numbers from Exagen Inc. show promising results, with revenues exceeding forecasts by 4.4% and statutory losses per share coming in 4.4% smaller than expected. Following these results, analysts have adjusted their earnings model, with revenue forecasts for 2024 now at US$54.2 million, reflecting a 3.1% improvement compared to the last 12 months. Despite the steady losses expected, the consensus price target remains unchanged at US$5.50 per share, indicating that the business is performing in line with estimates. However, there are varying analyst views, with price targets ranging from US$5.00 to US$7.00 per share. It's worth noting that while Exagen's revenue growth is projected to slow down, the wider industry is expected to grow faster. This suggests that while Exagen's performance may be steady, it may lag behind industry peers in terms of growth.
